$Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia$

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Brandi Anders, Lauren Veltri, Abraham S. Kanate, Alexandra Shillingburg, Nilay Shah, Michael Craig, Aaron Cumpston
Format:	Article
Language:	English
Published:	Wiley 2017-01-01
Series:	Advances in Hematology
Online Access:	http://dx.doi.org/10.1155/2017/6464972
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
by: Jessica Parrott, et al.
Published: (2017-01-01)

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia
by: Yu Zhang, et al.
Published: (2025-02-01)

Case report: Dysphonia associated with high-dose cytarabine therapy
by: Ling Ma, et al.
Published: (2025-01-01)

Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness
by: Linu A. Jacob, et al.
Published: (2015-01-01)

Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
by: Julia M. Unglaub, et al.
Published: (2025-01-01)

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study
by: Muhit Özcan, et al.
Published: (2025-01-01)

Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin
by: Jinhua Piao, et al.
Published: (2022-01-01)

Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
by: Jin Yin, et al.
Published: (2024-12-01)

Sacral Myeloid Sarcoma Manifesting as Radiculopathy in a Pediatric Patient: An Unusual Form of Myeloid Leukemia Relapse
by: Joana Ruivo Rodrigues, et al.
Published: (2018-01-01)

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population
by: Ashley L. Ross, et al.
Published: (2013-01-01)

High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea
by: WonGun Kwack, et al.
Published: (2016-01-01)

Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy
by: Ying Du, et al.
Published: (2025-01-01)

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
by: Ignacio I Wistuba, et al.
Published: (2024-07-01)

High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease
by: Prahlad Ho, et al.
Published: (2014-01-01)

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
by: Kazuya Sato, et al.
Published: (2021-01-01)

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases
by: Ingolf Molle, et al.
Published: (2022-01-01)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
by: Eko A. Pangarsa, et al.
Published: (2021-01-01)

Salvage Therapy for Refractory Aids-Related Primary Central Nervous System Lymphoma
by: Hugo Ferro, et al.
Published: (2012-01-01)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
by: Håkon Reikvam, et al.
Published: (2018-01-01)

Cyclosporine Regimens in Plaque Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment Approaches
by: M. D. Colombo, et al.
Published: (2013-01-01)

Mexiletine dosing and tolerability in refractory chronic migraine: Insights from post-lidocaine infusion treatment
by: Lucia Liao, et al.
Published: (2025-02-01)

Super-Refractory Status Epilepticus Treated with High Dose Perampanel: Case Series and Review of the Literature
by: Christopher R. Newey, et al.
Published: (2019-01-01)

Efficacy of low-dose rituximab versus immunosuppressants in refractory orbital inflammatory pseudotumors with intracranial extension
by: Yuyu Li, et al.
Published: (2025-01-01)

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
by: Jorge E. Cortes, et al.
Published: (2025-01-01)

Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
by: Bacharach J, et al.
Published: (2025-01-01)

Isolated central nervous system relapse in blast crisis of chronic myeloid leukemia: a case report
by: Hari Priya Raghvan, et al.
Published: (2025-01-01)

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
by: Marka Crittenden, et al.
Published: (2021-04-01)

A Novel Split-Course High-Dose Palliative Radiotherapy Regimen for Locally Advanced Sinonasal Cancer: A Case Report
by: Saif Aljabab, et al.
Published: (2024-01-01)

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
by: Monika Conchon, et al.
Published: (2009-01-01)

The Dose Makes the Poison
by: Kerry Carney
Published: (2025-12-01)

High-Dose Glycine Treatment of Refractory Obsessive-Compulsive Disorder and Body Dysmorphic Disorder in a 5-Year Period
by: W. Louis Cleveland, et al.
Published: (2009-01-01)

Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies
by: Anna P. Kempke, et al.
Published: (2016-01-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen
by: Majed A. Alshamrani, et al.
Published: (2019-01-01)

Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis
by: Etsuko Matsubara, et al.
Published: (2016-01-01)

Accuracy-dependent dose-constraints and dose-based safety margins for organs-at-risk in radiotherapy
by: Joep C. Stroom, et al.
Published: (2025-01-01)

Absorbed Dose Measurements for Teletheraphy Prediction of Superficial Dose Using Halcyon Linear Accelerator
by: Raymond Njinga, et al.
Published: (2024-07-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)